Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition.

Martinez-Useros J, Garcia-Carbonero N, Li W, Fernandez-Aceñero MJ, Cristobal I, Rincon R, Rodriguez-Remirez M, Borrero-Palacios A, Garcia-Foncillas J.

J Clin Med. 2019 Apr 25;8(4). pii: E560. doi: 10.3390/jcm8040560.

2.

[Prognostic factors in adenocarcinoma of the ampulla of Vater].

Fernández Aceñero MJ, Martínez Useros J, Díez-Valladares L, Ortega-Medina L, Pérez Aguirre E, de la Serna Esteban S, García Botella S, Díaz Del Arco C.

Rev Esp Patol. 2018 Oct - Dec;51(4):210-215. doi: 10.1016/j.patol.2018.03.001. Epub 2018 Apr 13. Spanish.

PMID:
30269771
3.

New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review.

Garcia-Carbonero N, Li W, Cabeza-Morales M, Martinez-Useros J, Garcia-Foncillas J.

Int J Mol Sci. 2018 Aug 21;19(9). pii: E2468. doi: 10.3390/ijms19092468. Review.

4.

Identification of prefrontal cortex protein alterations in Alzheimer's disease.

Garranzo-Asensio M, San Segundo-Acosta P, Martínez-Useros J, Montero-Calle A, Fernández-Aceñero MJ, Häggmark-Månberg A, Pelaez-Garcia A, Villalba M, Rabano A, Nilsson P, Barderas R.

Oncotarget. 2018 Jan 24;9(13):10847-10867. doi: 10.18632/oncotarget.24303. eCollection 2018 Feb 16.

5.

Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.

Martinez-Useros J, Li W, Georgiev-Hristov T, Fernandez-Aceñero MJ, Borrero-Palacios A, Perez N, Celdran A, Garcia-Foncillas J.

Pathol Oncol Res. 2019 Jan;25(1):269-278. doi: 10.1007/s12253-017-0341-0. Epub 2017 Nov 3.

PMID:
29101736
6.

PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.

Cristóbal I, Torrejón B, Martínez-Useros J, Madoz-Gurpide J, Rojo F, García-Foncillas J.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):435-438. doi: 10.1016/j.bbcan.2017.08.005. Epub 2017 Sep 12. Review.

PMID:
28916342
7.

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.

Martinez-Useros J, Georgiev-Hristov T, Fernández-Aceñero MJ, Borrero-Palacios A, Indacochea A, Guerrero S, Li W, Cebrián A, Gómez Del Pulgar T, Puime-Otin A, Del Puerto-Nevado L, Rodríguez-Remírez M, Pérez N, Celdrán A, Gebauer F, Garcia-Foncillas J.

PLoS One. 2017 Aug 1;12(8):e0182044. doi: 10.1371/journal.pone.0182044. eCollection 2017.

8.

Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment.

Martinez-Useros J, Li W, Cabeza-Morales M, Garcia-Foncillas J.

J Clin Med. 2017 Mar 9;6(3). pii: E29. doi: 10.3390/jcm6030029. Review.

9.

The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.

Martinez-Useros J, Garcia-Foncillas J.

Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18. Review.

10.

UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis.

Wurth L, Papasaikas P, Olmeda D, Bley N, Calvo GT, Guerrero S, Cerezo-Wallis D, Martinez-Useros J, García-Fernández M, Hüttelmaier S, Soengas MS, Gebauer F.

Cancer Cell. 2016 Nov 14;30(5):694-707. doi: 10.1016/j.ccell.2016.10.004. Epub 2016 Oct 27.

11.

Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy.

Cebrián A, Gómez Del Pulgar T, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Marín-Arango JP, Caramés C, Vega-Bravo R, Rodríguez-Remírez M, Manzarbeitia F, García-Foncillas J.

Pathol Res Pract. 2016 Dec;212(12):1133-1137. doi: 10.1016/j.prp.2016.09.012. Epub 2016 Sep 22.

PMID:
27712975
12.

Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Martinez-Useros J, Garcia-Foncillas J.

Biomed Res Int. 2016;2016:4873089. Epub 2016 Sep 1. Review.

13.

Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study.

Del Puerto-Nevado L, Marin-Arango JP, Fernandez-Aceñero MJ, Arroyo-Manzano D, Martinez-Useros J, Borrero-Palacios A, Rodriguez-Remirez M, Cebrian A, Gomez Del Pulgar T, Cruz-Ramos M, Carames C, Lopez-Botet B, Garcia-Foncillas J.

BMC Cancer. 2016 Jul 25;16:519. doi: 10.1186/s12885-016-2574-9.

14.

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.

Aguilera O, Muñoz-Sagastibelza M, Torrejón B, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Rodriguez-Remirez M, Zazo S, García E, Fraga M, Rojo F, García-Foncillas J.

Oncotarget. 2016 Jul 26;7(30):47954-47965. doi: 10.18632/oncotarget.10087.

15.

Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.

Gómez Del Pulgar T, Cebrián A, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Marín-Arango JP, Caramés C, Vega-Bravo R, Rodríguez-Remírez M, Cruz-Ramos M, Manzarbeitia F, García-Foncillas J.

J Cell Mol Med. 2016 Sep;20(9):1729-36. doi: 10.1111/jcmm.12879. Epub 2016 May 12.

16.

Obesity and colorectal cancer: molecular features of adipose tissue.

Martinez-Useros J, Garcia-Foncillas J.

J Transl Med. 2016 Jan 22;14:21. doi: 10.1186/s12967-016-0772-5. Review.

17.

Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.

Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A.

Oncotarget. 2015 Mar 20;6(8):5903-17.

18.

The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.

Martinez-Useros J, Garcia-Foncillas J.

Oral Oncol. 2015 May;51(5):423-30. doi: 10.1016/j.oraloncology.2015.02.092. Epub 2015 Mar 6. Review.

19.

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.

Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J.

BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965.

20.

PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.

Cristóbal I, Manso R, Rincón R, Caramés C, Senin C, Borrero A, Martínez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Mol Cancer Ther. 2014 Apr;13(4):938-47. doi: 10.1158/1535-7163.MCT-13-0150. Epub 2014 Jan 21.

Supplemental Content

Loading ...
Support Center